Mineralys Therapeutics MLYS 深 沪
等待开盘 05-19 09:30:00 美东时间
26.39
-0.990
-3.62%
华盛通- 最 高27.55
- 今 开27.50
- 成交量 96.77万股
- 最 低 26.045
- 昨 收 27.38
- 总市值 21.77亿
- 52周最高 47.65
- 市盈率 静 --
- 换手率 1.17%
- 52周最低 12.59
- 委 比 70.76%
- 总股本 8249.81万
- 历史最高 47.65
- 量 比 1.09
- 振 幅 5.50%
- 历史最低 5.85
- 每 手 1
- 风险率 10.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Mineralys Therapeutics To Feature Data From Phase 3 Launch-HTN Trial At ESH 2026
– Oral presentation highlights efficacy and safety profile of lorundrostat in patients with uncontrolled hypertension and chronic kidney disease –
今天 04:10
AstraZeneca Scores Key FDA Wins Across Cardiovascular And Oncology Portfolios
AstraZeneca wins FDA approvals for Baxfendy in hypertension and Enhertu in early HER2-positive breast cancer treatment.
今天 00:59
AstraZeneca's blood pressure drug wins U.S. approval
AstraZeneca's blood pressure drug wins U.S. approval Baxfendy works by blocking aldosterone, targeting hormonal causes of high blood pressure Drug is also being tested for chronic kidney disease and heart failure AstraZeneca expects it will bring in more than $5 billion in peak annual sales By Bhanv
05-18 14:00
Mineralys CMO David Malcom Rodman disposes of shares worth $648,330.57
Mineralys CMO David Malcom Rodman disposes of shares worth $648,330.57 Mineralys Therapeutics Chief Medical Officer Rodman David Malcom reported sales of 22,575 common shares on May 11-13, leaving 63,443 shares owned. Sales were executed at weighted-average prices of USD 29.71, USD 29.36, USD 28.58.
05-14 09:42
财报速睇 | Mineralys Therapeutics 2026财年Q1营收0.00亿美元，同比增长0.0%；归母净利润亏损0.39亿美元，同比亏损缩窄7.1%
华盛资讯5月7日讯，Mineralys Therapeutics公布2026财年Q1业绩，公司Q1营收0.00亿美元，同比增长0.0%，归母净利润亏损0.39亿美元，同比亏损缩窄7.1%。
05-07 05:05
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Mineralys Therapeutics announced the FDA acceptance of its NDA for lorundrostat to treat hypertension, with a PDUFA target date of December 22, 2026. The company highlighted its strong progress in advancing lorundrostat, supported by five positive clinical trials demonstrating significant blood pressure reduction and favorable safety. Financially, the company reported $646.1 million in cash and investments as of March 2026, with reduced R&D expen...
05-06 20:05
TD Cowen Initiates Coverage On Mineralys Therapeutics with Buy Rating
TD Cowen analyst Tara Bancroft initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Buy rating.
04-28 01:06
Mineralys CMO David Malcom Rodman sells 2,170 shares worth $59,405
Mineralys CMO David Malcom Rodman sells 2,170 shares worth $59,405 Mineralys Therapeutics Chief Medical Officer Rodman David Malcom sold 2,170 shares on April 9 at USD 27.38. Transaction followed exercise of 2,170 stock options at USD 16. Malcom held 76,140 shares directly after transactions. Discla
04-14 09:14
